

In accordance with the provisions of article 226 of Law 6/2023, of 17 March, on Securities Markets and Investment Services (the "LMVSI") and other concordant provisions, **FAES FARMA, S.A.**, in compliance with the Securities Market Law, notifies the **NATIONAL SECURITIES MARKET COMMISSION** of the following:

INSIDER INFORMATION

Faes Farma, S.A. has signed a contract for the acquisition of Laboratorios Edol

Faes Farma, S.A., announces that it has today signed a contract, subject to conditions precedent, for the acquisition of 100% of the shares of Laboratorios Edol Productos Farmacêuticos, S.A. ("Laboratórios Edol"), a pharmaceutical laboratory based in Portugal, and the following associated companies of Laboratórios Edol: Setriworld - Promoção e Investimento, S.A.; VAPP Produção e Comercialização de Produtos para Veterinária, Lda; and Farmacêutica Austral, Lda.

Founded in 1952, Laboratorios Edol specialises in ophthalmology products and has a recent production factory in Portugal. Laboratorios Edol has a leading position in the ophthalmology area in Portugal and its products are complementary to Faes Farma's portfolio

This acquisition, valued at 75 million euros, from which net financial debt will be deducted, represents a new strategic milestone in Faes Farma's commitment to growth and internationalisation, and also strengthens its position in the Portuguese market, where the Faes Farma Group has been present for more than 80 years. With this operation, Faes Farma will double both its sales and EBITDA in Portugal. In addition, the expected synergies derived from future optimisations and internationalisation of Laboratorios Edol's product portfolio will be added.

Laboratorios Edol has reached an annual turnover in 2024 of over 30 million euros, and has a portfolio of products and registrations that will enable Faes Farma to strengthen its



expansion and positioning in markets other than Portugal, taking advantage of Faes Farma's existing commercial networks, both in Spain and in international markets.

Ophthalmology, an area in which Faes Farma already has experience in the development and launch of bilastin ophthalmic, represents a key strategic opportunity, with expected double-digit growth. This growth is driven not only by the ageing population, which leads to diseases such as glaucoma and dry eye, but also by the increase in symptoms caused by seasonal allergies and prolonged use of screens.

In short, this operation is part of Faes Farma's international growth strategy, reinforcing its direct presence in Portugal and supporting business growth through new therapeutic areas, creating synergies with the current R&D&I team.

The closing of the transaction is subject to the satisfactory fulfilment of several conditions precedent which are expected to be met by the end of June 2025.

25 March 2025